A term that was created in 2010 called “liquid biopsy” became the standard for much of the screening of cancer that is done using blood to check for cancer cells though the NCI definition is specific for cancer and used to include its applications in detecting cancer and determining therapeutic efficacy : https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy
The first one that was approved by the FDA was in 2016 for Non small cell lung cancer using EGFR mutation test v2 in plasma and since then FDA has issued guidance for the industry in 2024 that can help the industry plan for these tests.
